RBC Capital analyst Kurt Hallead maintained a Buy rating on Core Laboratories (NYSE:CLB) N.V. on Friday, setting a price target of $32, which is approximately 28.98% above the present share price of $24.81.
Hallead expects Core Laboratories N.V. to post earnings per share (EPS) of $0.07 for the fourth quarter of 2020.
The current consensus among 6 TipRanks analysts is for a Hold rating of shares in Core Laboratories, with an average price target of $26.4.
The analysts price targets range from a high of $33 to a low of $18.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $105.38 million and a net profit of $10.53 million. The company's market cap is $1.1 billion.
According to TipRanks.com, RBC Capital analyst Kurt Hallead is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -9.5% and a 32.65% success rate.
Core Laboratories NV engages in the provision of proprietary and patented reservoir description, production enhancement, and reservoir management services to the oil and gas industry. It operates through the following business segments: Reservoir Description and Production Enhancement. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid, and gas samples and provides analytical and field services to characterize properties of crude oil and petroleum products. The Production Enhancement segment provides products and services relating to reservoir well completions, perforations, stimulations, and production. The company was founded in 1936 and is headquartered in Amsterdam, the Netherlands.